Ocular allergy (OA) includes a group of common and less frequent hypersensitivity disorders frequently misdiagnosed and not properly managed. The diagnosis of OA is usually based on clinical history and signs and symptoms, with the support of in vivo and in vitro tests when identification of the specific allergen is required. To date, no specific test is available for the diagnosis of the whole spectrum of the different forms of OA. The lack of recommendations on diagnosis of OA is considered a medical need not only for allergists but also for ophthalmologists. This position paper aims to provide a comprehensive overview of the currently available tools for diagnosing OA to promote a common nomenclature and procedures to be used by different specialists. Questionnaires, sign and symptom grading scales, tests and potential biomarkers for OA are reviewed. We also identified several unmet needs in the diagnostic tools to generate interest, increase understanding and inspire further investigations. Tools, recommendations and algorithms for the diagnosis of OA are proposed for use by both allergists and ophthalmologists. Several unmet needs in the diagnostic tools should be further improved by specific clinical research in OA.
Introduction and Current Classification of Ocular Allergy
The term allergic conjunctivitis (AC) or ocular allergy (OA) refers to a collection of ocular surface disorders that affects the eyelid and conjunctiva. IgE-and non-IgEmediated hypersensitivity disorders include intermittent/seasonal and persistent/perennial allergic conjunctivitis (SAC and PAC according to the historical nomenclature and classification), the diseases vernal and atopic keratoconjunctivitis (VKC and AKC) and contact blepharoconjunctivitis (CBC) (1) ( Table 1) . These clinical subtypes are diagnosed and managed by ophthalmologists, allergists, pediatricians and rhinologists usually considering clinical history and signs and symptoms, aided by in vivo and in vitro tests when identification of the specific allergic sensitization is required (1). While clinical characteristics can provide a relatively convincing diagnosis, in their initial or chronic stages there can be some confusion as to which form of allergy is present. At times, pseudo-allergic forms, with clinical manifestations similar to allergy but with a non-allergic equivocal pathogenesis, are difficult to distinguish from OA forms. In fact, several ocular surface diseases, including tear film dysfunction, blepharitis, infections, toxic and mechanical conjunctivitis, may mimic the clinical pictures of OA (1). To date, there is no specific clinical and laboratory evaluation suitable for the diagnosis and monitoring of OA. Ancillary tests, such as skin prick test and the identification of serum-specific IgE, can be useful for diagnosis and management, however it is well known that the results may not correlate with the ocular disease triggers. As in many other diseases, accurate, rapid diagnosis and, in particular, the paucity of guidelines on OA diagnosis, represent major unmet needs (2) . This EAACI Task Force aims to provide a comprehensive overview of the currently available tools to make recommendations concerning the diagnosis of OA in daily clinical practice. 
Methods

NOT (Stevens OR retina OR uveitis OR optic nerve).
Manual searches of the reference lists of selected studies were performed and relevant studies identified. Experts were contacted to suggest other studies not previously revealed from the database search. Studies were considered if they included human subjects, irrespective of age and race, and addressed diagnostic procedures, diagnostic utilities, regardless of the type of OA. No time or language limitations were established. Papers were selected according to the information provided on the title and abstract. Each topic was reviewed by two independent experts, and finally included and analyzed by the whole panel. Evidence to support each point was reviewed and a consensus decision was made for each chapter. As evidence regarding a diagnostic procedure was limited, some of the recommendations were based on consensus-driven proposals by the task force working group.
Patient's clinical history Rationale
The patient's medical history is the first crucial step in the diagnosis of OA, especially in the differential diagnosis of "Red Eye", one of the most common ophthalmic conditions (3) . A well-performed medical history may help to understand the etiology of the conjunctivitis. The medical history should cover types of symptoms (itching, burning, photophobia, discharge, visual changes, pain), whether there is unilateral or bilateral eye involvement, duration of symptoms, presence of allergies or systemic diseases, previous treatments, family history, environmental and occupational exposures, use of contact lenses and any type of ocular medication and surgery (1).
Signs and symptoms
Ocular itching is the hallmark subjective symptom of OA. It indicates the release of histamine from conjunctival mast cells and the activation of H1 receptors on nerve endings (1). Eyelid itching frequently occurs in blepharitis patients especially if related to eyelash infestation. Ocular redness (hyperemia) is the primary sign of OA due to conjunctival vasodilatation, which is often diffuse. Localized hyperemia is suggestive of subconjunctival hemorrhage or episcleritis. Photographic scales can be helpful in minimizing subjective observer variability. Tearing or "watery eyes", is a non-specific consequence of the lacrimal gland response-reflex to several stimuli involving conjunctival and nasal sensory nerve endings. Tearing is associated with OA but also other forms of ocular surface diseases such as infectious and mechanical conjunctivitis, and with evaporative dry eye. Edema is easy to observe when limited to eyelid swelling but can also involve the conjunctiva, resulting in chemosis. This symptom is easy to observe if intense. When mild or moderate, slit lamp examination is required. Pain is not a typical symptom of OA, but indicates a corneal involvement in VKC and AKC. Allergic patients may report mild visual disturbances, blurring or normal vision. Visual impairment is a sign of corneal involvement in VKC and AKC. Discharge is usually watery or serous; mucopurulent or purulent discharge suggests infectious conjunctivitis; bilateral discharge upon wakening is a sign of blepharitis; sticky mucous discharge and tearing, especially if associated with severe photophobia, are significant indicators of VKC and AKC. Bilateral involvement is typical for OA. Asymmetrical forms are possible. In viral conjunctivitis, the symptoms are often unilateral at onset and become bilateral after one or two days. Time of onset of the first symptoms of SAC and PAC is during adolescence and young adulthood (80% of patients are younger than 30 years old) and infrequently in older patients (4) . In boys VKC begins rarely before the age of 3 or after puberty, and usually subsides after puberty (5) . It is observed more commonly in warm climates (6) . In AKC, symptoms may appear at 30-50 years of age, sometimes years after being diagnosed with atopic dermatitis or asthma (7) . Overlaps or evolutions from VKC to AKC may occur. In intermittent OA/SAC, the onset and duration of symptoms are limited to the pollen season or to the local seasonal variability of specific allergens including mites. Symptoms recur every season but are self-limiting (8) . In persistent OA/PAC, symptoms are usually mild but persistent, exacerbating after increased or chronic exposure to allergens such as house dust mites, animal dander, occupational allergens (9, 10), or to non-specific irritating factors. PAC and AKC may also present with seasonal exacerbations. VKC worsens in the spring and summer. If severe, symptoms can be observed all year round. In CBC, attention should be made to substances applied into or around the eye (medications, cosmetics, etc.) (9) . If suspected, a work-related allergy has to be confirmed by worsening of symptoms in the workplace (1, 10). In CBC the delay between the exposure to the allergen and the occurrence of symptoms is usually longer. Some non-specific factors like smoke, pollution or wind can increase symptoms of OA (11) . In addition, food or food additives may influence OA. Many patients have a history of co-morbidity with other allergic diseases. Conjunctival symptoms are present in 30-71% of patients with allergic rhinitis (AR) (11) . AC alone has been estimated in 6-30% of the general population and in up to 30% of children, alone or in association with AR (12) . Up to 40-75% of VKC patients suffer from other allergic diseases (12) . AKC is present in up to 40% of atopic dermatitis patients and the co-morbidity with atopic dermatitis and asthma is around 90% (13) . It is always necessary to consider patients' activity limitations, sleep problems, coexisting nose, respiratory and cutaneous problems but also practical and emotional aspects.
Recommendations
• Accurate medical and personal history is fundamental for diagnosis.
• Consider different causes of red eye.
• Always ask for ocular signs and symptoms in other allergic co-morbidities.
• Investigate triggers for signs and symptoms.
• Refer to an ophthalmologist especially in cases of severe symptoms, unilateral redness, ocular pain, visual disturbance or long term use of topical drugs Unmet needs
• Primary care awareness in OA.
• Standardized questionnaire to be used by both ophthalmologists and allergists
Clinical Ocular Examination
Rationale Diagnosis of OA relies on the combination of a suggestive medical history and conjunctivitis signs ( Figure 1 and Table 1 ). Some relevant clinical signs can be assessed by non-ophthalmologists ( (Figure 2 ). Lid eczema is a specific marker for AKC. Ophthalmological examination reveals conjunctival papillary hypertrophy, follicles, scarring, blepharitis (lid margin inflammation), meibomian gland dysfunction (MGD) ( Figure 3 ) and tear instability, an important sign of dry eye. Corneal involvement, found only in VKC and AKC, is a marker of severity. Superficial corneal epitheliopathy, neovascularization and scars are non-specific, whereas shield ulcers and plaques are much more suggestive of severe VKC and AKC (Figure 4 ).
Techniques
Observation, by daylight or direct light, of the face, lids, lid margin, palpebral and bulbar conjunctiva is the first approach. To evaluate the superior palpebral conjunctiva, use lid eversion. More accurate ocular examination requires the use of a slit lamp. Corneal and conjunctival epitheliopathy are assessed by fluorescein staining usually under slit lamp evaluation ( Figure 4 ).
Recommendations
• Always look at the eyelid skin and the lid margin.
• When slit-lamp is not available, look at the eye using natural light.
• Examination by an ophthalmologist is required in atypical or severe cases.
Scoring OA and quality of Life
Rationale and Definitions Different scales and criteria have been used, highlighting the difficulties encountered in grading acute and chronic manifestations. Main indications for scoring signs and symptoms include evaluating the disease severity, assessing the response to conjunctival and nasal provocation tests (CPT and NPT), and the efficacy of therapeutic agents.
Health-related quality-of-life (QoL) has been defined as "the functional effects of an illness and its resulting therapy upon a patient, as perceived by the patient". OA may significantly impact activities like reading, computer or tablet use, recreation, games, sports, television, movies and electronics. These disturbances generate worries, anxiety and some psychological discomfort for the patient and family, and impact on daily tasks, work, leisure, sleep and mood. To date, no specific QoL questionnaire has been validated for OA, except for VKC. In terms of important patient-reported outcomes, the ocular component of AR impacts patient QoL in meaningful ways (14) .
Instruments
Grading Signs and Symptoms
The visual analogue scale (VAS), mainly used in clinical trials (15) , is a useful semiquantitative method to express the intensity of symptoms by the patients. The selfrecording is performed on a 100mm scale without marked intervals by indicating the most severe symptoms on the far right and the absence of symptoms on the far left.
The severity of subjective symptoms may also range from 0 to 10.
Grading questionnaires
The score may be based on the duration of symptoms: 0= no symptom, 1= "some of the time", 2= "half of the time", 3 = "most of the time", 4 = "all the time". The QoL in VKC children (QUICK) questionnaire (16), uses a three-point scale: 1= never, 2= sometimes, 3= always. The total sum score obtained determines the status of the disease.
Ocular Severity scores
The "Severity Index" (SI)-system is based on the patient's subjective assessment of the severity of each particular symptom and the grade of severity of objective findings: 0= no signs or symptoms, 1= mild, 2= moderate, 3= severe. The SI is calculated as the total score of individual signs and symptoms (Appendix 1). In 2012 (1, 17), we proposed a severity classification of OA based on ARIA guideline criteria (17) ( Table 3 ). For severe and chronic forms (VKC, AKC) a 3 grade score for corneal ulcer assessment has been used -grade 1: ulcers that extend the beyond the epithelial basal membrane and yet have a transparent base; grade 2: ulcers with opaque base and partially filled with inflammatory debris; grade 3: ulcers filled with debris (plaque) remaining above the surrounding epithelium.
Scores for evaluating therapy
The recent recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis (RC) (18) suggested: a homogeneous terminology for nasal and conjunctival symptoms using six organ-related categories (itchy nose, sneezing, runny nose, blocked nose, itchy/red eyes, watery eyes) in the daily symptom score (dSS); a stepwise use of rescue medication added in the daily medication score (dMS); a scoring system for a combined symptom and medication score (CSMS), based on an equal weight of the dSS and of the dMS. This scoring system follows the EMA guideline, the World Allergy Organization (WAO) recommendations (19, 20) .
QoL evaluation and questionnaires
Generic QoL questionnaires assessing the global health status, like the Short Form 36 and 20 (SF-36 and SF-20), the EuroQoL (EQ-5D), and the Sickness Impact Profile (SIP) (21) or the KINDL questionnaire in children (22) , are the most frequently used.
QoL in OA
In the absence of specific questionnaires for OA, those validated for RC can be used: the Juniper's questionnaire (RQLQ) (23); its shortened version (mini-RQLQ) (24); specific questionnaires for adolescents and children (25, 26) . The RQLQ includes 28 items divided amongst 8 domains. The mini-RQLQ has been reduced to 14 items and 5 domains: activity limitations, practical problems, nasal symptoms, ocular symptoms and other symptoms. OA is addressed in 5 symptoms in the RQLQ and 4 in the mini-RQLQ: need to rub nose/eyes, itchy eyes, sore eyes, watery eyes, and swollen eyes. Interestingly, the analysis of 4 clinical trials revealed that the highest scoring items were the "need to rub eye/nose" and "itchy eyes" (24). In a large cohort of 1009 rhinitis patients, the presence of ocular symptoms statistically increased the RQLQ score by +0.5 (27) . The smallest improvement in RQLQ score considered worthwhile by a patient affected by grass-pollen allergic RC was consistently estimated as 1 (28) . VKC and AKC should probably be considered separately, because the impact on QoL is often intense. The QUICK questionnaire, developed for VKC (16) , contains 16 items pooled in 2 domains: symptoms; daily activities. In contrast to children with RC (26), daily activities (going to the swimming pool, practicing sports, meeting friends) were significantly impacted by VKC.
Impact on economic costs
SAC patients experienced QoL reductions in general health and specific aspects of vision and productivity, but also a significant economic cost to treat their condition when assessed by the Health Economic and Demographic Questionnaire (HEDQ) (29) . This aspect must be taken into account for both private and public health care modalities when attempting to ascribe a total cost to a medical condition.
Recommendations
• Score signs and symptoms for diagnosis and monitoring.
• Use VAS system to evaluate patients' perspective.
• Assess the OA impact on QoL.
• Use EuroQoL (EQ-5D) to gain basic information on general QoL.
• In the absence of a specific questionnaire on OA, use the mini-RQLQ.
• QUICK is the only specific and validated questionnaire for VKC Unmet needs
• Correlation among currently available severity scoring systems is unknown.
• Specific QoL questionnaires should be developed to study the impact of OA on vision, general and psychological condition in different ages.
• An ideal tool could measure disease, symptoms perception and treatment efficacy by the patient.
Allergy testing in OA Rationale and definitions
During the process of diagnosing OA, the allergen may be considered as either the main trigger of symptoms, closely associated with non-allergenic factors, or unrelated to clinical symptoms. The relationship between allergen sensitivity and allergen exposure is easy to assess, particularly in SAC. Allergen investigations may be unnecessary in cases where symptoms resolve with symptomatic treatment, or when symptoms occur after an obvious allergen exposure. If symptoms persist or recur regardless of treatment, allergen identification is required. In the majority of cases, skin prick tests (SPT) are unanimously considered the gold standard and the first-line approach for identifying IgE-mediated sensitization, due to their efficiency, safety and relatively low cost (30) . Biological assays such as specific IgE measurement, are used to confirm sensitization in specific cases. Nevertheless, polysensitization (e.g a positive specific IgE to two or more allergens) is often found in patients with allergic rhinitis (31) . Once sensitization is demonstrated, its relevance for the patient can be investigated by the more specific conjunctival allergen provocation test (CAPT), particularly when polyallergy (e.g. clinical response to 2 or more allergens) is suspected or when clinical history suggests OA but SPT and IgE are negative or inconclusive (1) (31) (32) (33) . Procedures, indications and limitations of CAPT have been recently described (32) . When medical history suggests contact allergy, non-IgE mediated test are relevant, especially in cases of CBC (10) .
Techniques
The SPT should be performed with airway allergens, and be read according to rigorous methodology, according to EAACI recommendations (34, 35) . Indications for intradermal tests are limited to selected cases and allergens. Serum allergen-specific IgE measurements detect IgE sensitization over 0.1 IU/mL, although low levels (< 0.35 IU/mL) are less likely to be clinically relevant, are less sensitive than SPT (31, 36), and are not mandatory when SPT correlates with clinical history. Local sensitization may be suspected in OA, therefore microarray measurements of specific IgE in tears may be helpful (37) . Comparing serum and tear total IgE levels could be considered an indirect method for evidencing local allergy (37) . The Component Resolved Diagnosis (CRD), based on the pure allergen molecules (microarray or recombinant allergen-specific IgE detection), may be helpful in polysensitized or polyallergic patients. It can identify IgE antibody responses to crossreactive allergens present in foods and pollens and identify genuine primary sensitization, which is not possible with the use of allergen extracts. However, it is still rarely used in routine patient testing (38, 39) . The CAPT evaluates the inflammatory effects on the conjunctiva after topical allergen application (1, 32) triggering the same signs (redness, chemosis and lid swelling) and symptoms (itching and tearing) as those of a natural allergen exposure.
Contraindications are limited to uncontrolled allergy and chronic diseases. It requires an ophthalmic examination to rule out any ocular inflammation and a controlled protocol based on positivity criteria. Itching and redness are the main criteria to achieve a positive response when scored 2+ (Appendix 1) (40) . The IGOA TF on CAPT recommends the use of total ocular symptom score (TOSS; range 0-13) considered positive when it reaches 5 (32). Both early and late allergic responses can be monitored. Since CAPT may induce nasal symptoms, scoring them is useful. However, there is a lack of a standardized method for evaluating the combined ocular and nasal symptoms. Non-specific challenge tests are only used for research purposes. Patch tests aim to explore non-IgE-mediated allergy (41) . Haptens involved may be preservatives or additives in eye drops, cosmetics, or professional allergens.
Recommendations
• If SPT, IgE levels and allergen exposure history are in concordance, the involvement of an allergen can be assumed in SAC and PAC.
• CAPT should be considered in polysensitized or suspected polyallergic patients.
• CAPT is recommended when medical history suggests an allergen sensitization but SPT are negative.
• In VKC and AKC, allergen-specific triggering is less frequently involved.
• Patch tests are required in CBC.
Unmet needs
• Standardized methods for evaluating the ocular and nasal symptoms in response to CPT or NPT.
• Standardized specific IgE analysis for small tear volumes.
Visual Function
Rationale and Definition OA is not considered as a sight-threatening disorder. However, the clinical presentation ranges from mild forms not (or only slightly) influencing visual acuity (VA) to severe diseases (VKC and AKC), which affect the ocular structures, VA and QoL. Complications (corneal impairment, irregular astigmatism and scars, keratoconus, cataract, steroid-induced glaucoma) result in visual impairment (42) . Visual disturbances are also caused by symptoms (intense itching, watering, foreign body sensation, mucus discharge, eyelid pseudo-ptosis, ocular pain and photophobia). Few population-based data on VA impairment in OA are available since VA rarely represents a primary or secondary outcome in clinical trials.
Techniques
VA is measured by asking the subject to discriminate letters of known visual angle (Snellen and derived optotypes) or letters of equal recognition difficulty. The log of the minimal angle of resolution at a given distance and at high contrast (ETDRS and similar) uses an eye chart (optical instruments or computerized tests) at standard conditions. Since VA sometimes is difficult to measure in active VKC and AKC, QoL can be quantified as a surrogate criterion (43), but improves depending on the severity of corneal involvement (44) . All VKC and AKC patients should routinely undergo topographic corneal assessment because of the higher incidence of keratoconus (45, 46) .
Recommendations
• Consider visual acuity assessment in daily practice
• VKC and AKC subjects should undergo topographic corneal examination to rule out keratoconus
Ocular surface evaluation (Tear film function)
Rational and Definition
Ocular allergy and dry eye syndrome are the most common ocular surface inflammatory disorders. One does not preclude the coexistence of the other (47) . Chronic OA is causative of dry eye, which is classified as hypo-secretory (reduced tear production) or evaporative (due to low tear lipid layer thickness related to MGD) (48). Tear film instability was found in atopic children not only affected by allergic conjunctivitis but also rhinitis and asthma (49 
Recommendations
• Collect tear samples independently from both eyes because of possible asymmetrical conditions. • Prefer capillary tube collection since cells and mediators bind to the strips or sponges.
• The presence of one eosinophil by cytology is highly indicative of OA, whereas their absence does not exclude it.
• Tear collection and storage can influence protein detection Unmet need
• An assay kit for detecting a panel of tear mediators should be validated.
Imaging and emerging additional tests Rational
In-vivo imaging technologies have been widely used in the diagnosis, assessment of clinical severity and follow-up of ocular surface disorders. The application of these technologies may help to quantify the extent of inflammation and evaluate the efficacy of anti-allergic agents.
Definition and Techniques
In-vivo Confocal Microscopy (IVCM) is a real-time, non-invasive imaging technology, which enables microstructural analysis of the cornea in more physiological conditions at a cellular level (66) . IVCM creates a point source of light focused by an objective lens on the tissue. Compared to traditional slit lamp imaging, IVCM provides a higher magnification and depth of view, but examines only a limited area. With the recent in-vivo laser scanning CM (LSCM), it is possible to study the microscopic anatomy of semi-opaque structures, such as the conjunctiva and meibomian glands (MG). Morphological changes of superficial epithelial cells and nerves, increased presence of activated keratocytes, inflammatory cells, and Langerhans cells in the corneal stroma were shown in VKC and AKC by LSCM (67, 68) ( Figure 5 ). Following CPT, IVCM can be used to track and score the progress of the acute and late-phase allergic inflammation, capturing video images useful to study cell dynamics (scale 0-4; patent pending) (69) . IVCM may become useful for evaluating the efficacy of anti-allergic medications. In VCK and AKC, topical cyclosporine A (CsA) significant reduced the density of inflammatory cells (70, 71) .
Meibography is a non-invasive technique developed to observe MG structure. Using laser confocal meibography, shortening, distortion and dropout of MG may be observed in PAC (72, 73) .
Lipid layer Interferometry measures tear film stability and analyzes the depth of the lipid layer. Advanced tear instability and thickening of the tear film lipid layer were found in 80% of SAC patients (74) .
Photography:
Conjunctival hyperemia can be evaluated on the basis of digital photos using a modified grading scale or by using different digital image analysis software (75) .
Optical coherence tomography (OCT)
is an adjunctive, non-invasive, diagnostic method that can help the diagnosis of ocular surface lesions (76) . However, it is not routinely used in OA.
Recommendations
• Use new imaging techniques to more accurately assess the degree of inflammation in diagnosis, follow-up and treatment.
Diagnostic algorithm
The proposed diagnostic algorithm (Figure 1 ) is based on the clinical expertise of the authors and relevant recommendations from the literature (1, 3, 13, 33, 77) . The diagnosis of a suspected OA is based on medical history and the presence of suggestive signs and symptoms. In case of symptoms unusually not suggestive of OA, the differential diagnosis can be made, with the assistance of an ophthalmologist, considering the wide spectrum of disorders affecting the ocular surface. If signs and symptoms are suggestive of OA, primary skin or in vitro testing in addition to the clinical characteristic of each ocular disease (Tables 1 and 2 ), will improve the diagnosis. If primary diagnostic tools are uncertain or negative, secondary, more specific, local diagnostic tests may help to either define a specific ocular hypersensitivity disease or lead to a proper differential diagnosis.
Concluding Remarks
Characteristics of each diagnostic tool are summarized in Table 4 . Specific questionnaires on medical history and QoL for OA are still needed and the correlation among currently available severity scoring systems is largely unknown.
Ophthalmologists should refer their patients to the allergist any time there is a suspect of a specific sensitization and/or allergic co-morbidity. On the other hand, allergists should refer to the ophthalmologists all patients with severe ocular signs and symptoms, when ocular symptoms do not correlate with a specific sensitization or to rule out other non-allergic eye disorders. It is still not clear why, in some cases, the eye may be the only affected organ, or why some patients suffer from severe untreatable or chronic forms of OA only. Coordinated clinical and experimental studies are required to identify specific molecular and cellular mechanisms associated with each subtype of OA for developing new diagnostic tools and therapies. A. Persistence of symptoms 1-"Intermittent" means that the symptoms (itching and redness) are present:
Tables
• Less than 4 days a week • Or for less than 4 weeks 2-"Persistent" means that the symptoms (itching and redness) are present:
• More than 4 days a week • And for more than 4 weeks B. Severity of symptoms 1-"Mild" means that none of the following items are present:
• Vision disturbance • Impairment of daily activities, leisure and/or sport • Impairment of school or work • Troublesome symptoms 2-"Moderate" means that one of the following items are present:
• Vision disturbance • Impairment of daily activities, leisure and/or sport • Impairment of school or work • Troublesome symptoms 3-"Severe" means that two or more of the following items are present:
• Vision disturbance • Impairment of daily activities, leisure and/or sport • Impairment of school or work • Troublesome symptoms
The items: vision disturbance, impairment of daily activities/ leisure/ sport, impairment of school or work activities, troublesome symptoms, are quoted "yes" or "no". Accordingly the number of items affected, the disease is considered "mild" (0 items affected), "moderate" (1 item) or "severe" (2-4 items). The presence of signs and symptoms suggesting ocular allergy (OA) or the presence of signs and symptoms usually not associated with OA together with an accurate medical history is the first step in the diagnostic algorithm. In case of unusual signs and symptoms, the differential diagnosis can be made considering the wide spectrum of disorders affecting the ocular surface after consulting an ophthalmologist. When signs and symptoms suggest OA, primary skin or in vitro testing in addition to the clinical characteristic of each ocular disease (Tables 1 and 2 ) will consent to define a specific ocular allergic disorder. If primary diagnostic tools are uncertain or negative, secondary, more specific, local diagnostic test may help to either define a specific ocular hypersensitivity disease or suggest a proper differential diagnosis. Itching 0 = none 1 = mild (intermittent itching sensation) 2 = moderate (continual awareness but without the desire to rub) 3 = severe (continual awareness with the desire to rub the eyes) 4 = incapacitating itching (subject insists on rubbing eyes).
Redness 0 = none 1 = mild (perhaps localized within some quadrant) 2 = moderate (more marked and diffuse reddening in the quadrants) 3 = severe (very marked and diffuse reddening in the quadrants).
Tearing 0 = none 1 = mild (slightly humid eye) 2 = moderate (some tears, blows nose occasionally) 3 = severe (profuse tearing, tears rolling down cheeks) Chemosis 0 = none 1 = mild (detectable with slit lamp, conjunctiva raised from sclera) 2 = moderate (visually evident, raised conjunctiva, especially at the limbal area) 3 = severe (ballooning of conjunctiva)
